Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK
Non-Small Cell Lung Cancer (NSCLC) KOL Interview – UK
$599.00
This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.
Publisher: Biomedtracker
- Highlights
- Description
Highlights
…for some patients, for example that have a high disease burden but otherwise fit and well, I would prefer in the first-line setting to use the quadruplet, especially patients that have liver metastases, but not only limited to liver metastases, a high bulk of disease.
The patients that have PD-L1 expression more than 50%, about 20% of them will get the single-agent pembrolizumab, 80% will get the triplet. The patients that have less than 50% PD-L1 expression, the vast proportion will get the triplet, and a small proportion will get the quadruplet.
This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for non-small cell lung cancer (NSCLC). Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include AMG 510, MRTX849, capmatinib, tepotinib, TAK-788, poziotinib, pralsetinib, and selpercatinib.
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the